Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Company Overview - Enlivex Therapeutics Ltd. is a clinical-stage company focused on macrophage reprogramming immunotherapy, specifically developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to their homeostatic state [5]. Patent Issuance - The company announced the issuance of an Israeli patent numbered 290470, titled "THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS," which provides intellectual property protection in Israel until at least 2040 [1]. Clinical Trial Results - Enlivex reported positive topline data from the Phase IIa clinical trial (ENX-CL-05-001) for Allocetra™ in patients with moderate-to-severe knee osteoarthritis, showing a 24% reduction in knee pain and a 26% improvement in knee function compared to placebo [2][3]. - In patients with age-related primary osteoarthritis, there was a 72% reduction in knee pain and a 109% improvement in knee function compared to placebo, indicating a substantial and statistically significant effect [3]. Osteoarthritis Context - Osteoarthritis is the most common form of arthritis, affecting over 32.5 million Americans and more than 300 million individuals globally. By 2040, it is projected that 78 million Americans will have osteoarthritis [4]. - The condition leads to over one million hospitalizations annually in the U.S., primarily for total joint replacement, highlighting the critical need for effective treatments [4].